Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is... see more

CSE:RVV - Post Discussion

Revive Therapeutics Ltd. > Revive Therapeutics Provides Corporate Update on Psychedelic
View:
Post by DeadPool007 on Sep 21, 2020 9:05am

Revive Therapeutics Provides Corporate Update on Psychedelic

https://www.globenewswire.com/news-release/2020/09/21/2096539/0/en/Revive-Therapeutics-Provides-Corporate-Update-on-its-Psychedelics-Therapeutics-Programs.html
Comment by Chrisxd5 on Sep 21, 2020 9:06am
Fluff news.  Nothing crazy 
Comment by TheIceMan3 on Sep 21, 2020 9:13am
Far from fluff news, it's an important part of the company, a space that is growing HUGE and will be a massive money maker at some point in time or be part of why they get bought out.  MCUR is coming to market today and this is gonna be an awesome time for investors IMO. We can only listen to COOLIO/ Lil Ricky's BS so often.
Comment by 1ottrunner on Sep 21, 2020 9:17am
Agreed on all points.  This is the real future for Revive.
Comment by Chrisxd5 on Sep 21, 2020 9:31am
Future absolutely but for today will do nothing! 
Comment by RiskyBiz928 on Sep 21, 2020 9:21am
Shows they are not a one trick pony. Sillycybin (lol) is emerging - lots of potential. Keep the articles coming, great exposure.
Comment by Chrisxd5 on Sep 21, 2020 9:30am
Ok we will see with SP again.  Buddy your always wrong just stop 
Comment by TheIceMan3 on Sep 21, 2020 9:42am
The SP is going no where, that's not what I said, or anyone else who tried to explain it to you said.  You're not a very bright guy and you certainly aren't up for discussing what should be obvious to you. Weren't we suppose to be at .50 today, according to the other flunky COOLIO?  We are gonna do just fine on RVV but it won't be from your guys posting nonsense ...more  
Comment by Trippedstocks on Sep 21, 2020 10:12am
Worthless NR really. They combined the Aug 11 and Sept 2 news releases to create this "updated" news release. Thin film prototype Aug 11, university agreement Sept 2. Now how will they do a phase 1 study when the university of Wisconsin is a covid hot spot and on lockdown and virtually no one is on campus? Perhaps they should use Wisconsin for Bucillamine testing then they will have ...more  
Comment by RiskyBiz928 on Sep 21, 2020 10:18am
They are just keeping the 'buzz' going. Stay visible, stay relevant. EXPOSURE right now is in need to get some big investors on board.
Comment by mrnormal on Sep 21, 2020 10:40am
Great update. Should see our new partners in this area of study soon enough!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities